Clinical trials: Malignant Tumor Liver
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Cholangiocarcinoma, Hilar
Volume-Restricted Resection for Perihilar Cholangiocarcinoma
The goal of this observational study is to learn about the safety and long-term outcomes of volume-restricted liver resection in patients with perihilar cholangiocarcinoma (pCCA) who have an insufficient future liver remnant…
- Trial name
- NCT07149558
- Volunteers
- 300 people
- Sponsor
- Yongjun Chen
Hepatocellular Carcinoma
Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma
This an open-label study designed to evaluate the anti-tumour activity and safety of Prolarix in subjects with advanced hepatocellular carcinoma.
- Trial name
- NCT00746590
- Testing
- Prolarix (tretazicar co-administered with caricotamide)
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- BTG International Inc.
Liver Cancer, Ablation Techniques
The Safety and Efficacy of Irreversible Electroporation for the Treatment of Perivascular Liver Cancers
Malignant liver tumors are among the most common cancers worldwide, with over 10,000 new cases reported annually in Taiwan. Despite the availability of various treatment options, the prognosis for primary hepatocellular carcinoma…
- Conditions
- Liver Cancer, Ablation Techniques, Radiology
- Trial name
- NCT07214363
- Testing
- Irreversible Electroporation Ablation Generator
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma
TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)
The purpose of this protocol is to provide access to Therasphere treatment for patients with liver tumors.
- Trial name
- TheraSphere (NCT00683631)
- Testing
- TheraSphere HUD
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- University of Louisville
Carcinoma, Hepatocellular
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
This is a study to investigate the potential clinical benefit of refametinib when given in combination with sorafenib as first line treatment in patients with unresectable or metastatic HCC carrying a RAS mutation.
- Trial name
- NCT01915602
- Testing
- Refametinib (BAY86-9766), Sorafenib (BAY43-9006)
- Where
- 79 sites in United States, Austria and 19 more
- Volunteers
- 14 people
- Sponsor
- Bayer
Lung Cancer, Breast Cancer
Large Language Models Assist in Tumor MDT
Multidisciplinary teams (MDTs) represent the gold standard for personalized tumor treatment, but they are limited by medical resources and accessibility Limitation.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Stomach Cancer
- Trial name
- NCT07504367
- Testing
- LLM assists in MDT report writing
- Where
- 2 sites in China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hand-Foot Skin Reaction (HFSR)
ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction
This study aims to evaluate whether a combination of oral zinc supplementation and transdermal clobetasol cream is effective in preventing and reducing the severity of hand-foot skin reaction (HFSR) induced by regorafenib…
- Trial name
- ZINCLO-HAND (NCT06856590)
- Testing
- Zinc Supplementation, Clobetasol Propionate 0.05% Cream
- Where
- 13 sites in Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Gazi University
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma, Liver Metastases
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma
- Trial name
- NCT04676633
- Testing
- STP705
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sirnaomics
Solid Tumors, Hepatocellular Carcinoma (HCC)
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5).
- Conditions
- Solid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma, Pediatric Cancer
- Trial name
- NCT06636435
- Testing
- CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3
- Where
- 5 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Chiome Bioscience Inc.
Hepatocellular Carcinoma, Colorectal Cancer Liver Metastasis
The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
Multimodal thermal therapy (MTT), as an initiative integration of cryotherapy and radiofrequency heating, has been applied to treat various solid tumors.
- Trial name
- NCT07159048
- Testing
- Multimodal Tumor Thermal Therapy System, Radiofrequency Ablation System or Microwave Ablation System
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
This pilot phase II trial studies how effective pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy are at treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or…
- Trial name
- NCT03457948
- Testing
- Arterial Embolization, Pembrolizumab, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Nicholas Fidelman, MD
Liver Metastases, Colorectal Cancer
Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases
Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort underwent curative resection after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant…
- Conditions
- Liver Metastases, Colorectal Cancer, Surgery, Circulating Tumor DNA
- Trial name
- NCT06404593
- Testing
- Blood sampling
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma, Secondary Malignant Neoplasm of Liver
Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System
The goal of this study is to understand the immunologic effects radioembolization has on the immune system. This will be done by evaluating the changes on biopsy, peripheral blood monocytes, and cytokines.
- Trial name
- NCT03889093
- Testing
- Yttrium-90
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Minnesota
Liver Neoplasms
Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors
This study will evaluate the safety and effects of vaccine treatment plus radiation to the liver in patients with solid tumors that have spread to the liver.
- Trial name
- NCT00081848
- Testing
- rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM, rF-CEA(6D)/TRICOM, Recombinant Fowlpox-GM-CSF
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
The purpose of this study was to investigate the effect of only local radical treatment of liver metastases combined with systematic treatment in the treatment of patients with multiple organ metastases of colorectal cancer…
- Conditions
- Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT06449937
- Testing
- Radical local Surgery, Systemic therapy, Interventional therapy
- Where
- 6 sites in China
- Volunteers
- 130 people
- Sponsor
- Anhui Provincial Hospital
Tumor, Liver
PREDICTT Clinical Trial: Prospective Evaluation Of Pressure-Enabled Delivery And Alterations In CT-Based Tumor-To-Normal Liver Ratio And Tumor Dose Using The Trinav Infusion System
This single-arm prospective study will compare CT-based tumor-to-normal ratio (TNR) measurements obtained using TriNav versus endhole microcatheters.
- Trial name
- NCT07444645
- Testing
- Y90 Microsphere Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Cancer
Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01182272
- Testing
- sorafenib tosylate, laboratory biomarker analysis, neoadjuvant therapy
- Where
- France
- Volunteers
- 36 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Hepatocellular Carcinoma
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
This study is an open phase II clinical study, which consists of part a and Part B. Part a will evaluate the safety and tolerability of absk-011 combined with atilizumab in patients with advanced or unresectable HCC to And pk/pd…
- Trial name
- NCT05441475
- Testing
- ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w, ABSK-011 200mg BID combined with atilizumab 1200 mg q3w and bevacizumab 15mg/kg, ABSK-011 200mg BID combined with toripalimab 240 mg and bevacizumab biosimilar 15 mg/kg
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Abbisko Therapeutics Co, Ltd